Policy & Regulation
Janux reports positive Phase 1 data for JANX011, plans autoimmune trials in 2027
9 November 2026 - Biopharmaceutical company Janux Therapeutics Inc (Nasdaq: JANX) on Monday reported positive initial Phase 1 results for JANX011 in healthy volunteers, supporting plans to advance the...
Illumina expands MRD research portfolio with ultrasensitive sequencing technology
9 November 2026 - Genome research company Illumina Inc (NASDAQ: ILMN) announced on Monday that it has expanded its molecular residual disease (MRD) research portfolio with an early access programme fo...
Compass Pathways completes FDA application for COMP360 in treatment-resistant depression
9 November 2026 - Biotechnology company Compass Pathways plc (Nasdaq:CMPS) said on Monday that it has completed its New Drug Application (NDA) submission to the US Food and Drug Administration (FDA) f...
Charles River Laboratories to acquire Frontage bioanalysis and DMPK businesses for USD470m
9 November 2026 - Pharmaceutical research services provider Charles River Laboratories International Inc (NYSE:CRL) announced on Monday that it has entered into definitive agreements to acquire Fronta...
UCB and Biogen report additional positive Phase 3 data for investigational lupus treatment
9 November 2026 - Global biopharmaceutical company UCB (Euronext Brussels:UCB) and US biotechnology company Biogen Inc (NASDAQ:BIIB) on Monday announced additional clinical findings for dapirolizumab ...
Valneva reports positive Phase 2 results for tetravalent Shigella vaccine candidate
9 November 2026 - French vaccine company Valneva SE (Nasdaq:VALN) (Euronext Paris:VLA) on Monday announced positive results from two Phase 2 trials of S4V2, its tetravalent bioconjugate vaccine candid...